We are currently investigating intermittent issues affecting access to some articles and pages on our site. We apologize for any inconvenience and are working to resolve this as quickly as possible.

4 Newly Overvalued Stocks for the Month

Updated for January 2025: Barclays and Generali are among the stocks that are now expensive.

Bella Albrecht 17 January, 2025 | 4:20PM
Facebook Twitter LinkedIn

Illustration of the map of Europe with blue water and green land.

Each month, we screen the Europe-listed stocks under Morningstar’s coverage for newly overvalued names.

Over the past month, four stocks saw their Morningstar Ratings change to 2 stars, while none climbed into 1-star territory. Stocks rated 3 stars are fairly valued according to Morningstar analysts, while those rated 4 or 5 stars are considered undervalued.

For more information on the newly undervalued stocks, read our article.

The four new 2-star European stocks, ordered by market-cap, are:

• Assicurazioni Generali G

• Argenx ARGX

• Barclays BARC

• Be Semiconductor Industries BESI

All returns in this article are reported in the stock’s base currency and all data is sourced from Morningstar Direct.

Newly Overvalued Stocks as of Jan. 14

The Morningstar Europe Index fell 1.63% over the past month, leaving the overall European stock market moderately undervalued, hovering at a 5% discount to its fair value estimate on a cap-weighted basis.

Of the 255 Europe-listed stocks covered by Morningstar analysts:

• 49% are undervalued, 38% are fairly valued, and 13% are overvalued.

• Four are newly overvalued.

• Nine are newly undervalued.

• None moved from a 2-star rating to a 1-star rating.

• Among the newly overvalued stocks, none jumped from a 3-star rating to a 1-star rating.

• 12 are no longer overvalued.

Morningstar analysts assign every stock under their coverage a fair value estimate, which is an intrinsic measure of the stock’s worth, and an Uncertainty Rating, which captures the range of potential outcomes for that estimate. A higher Uncertainty Rating equates to a larger range of prices considered fairly valued.

These two metrics and the stock’s current price, are used to determine its Morningstar Rating.

Distribution of Star Ratings for Europe-Listed Stocks

Data is for Europe-listed stocks currently under analyst coverage.

Source: Morningstar Direct.

Metrics for this Month’s New 2-Star Stocks

Assicurazioni Generali G

• Morningstar Rating: ★★

• One-Month Return: 1.38%

Insurance firm Assicurazioni Generali has gained 7.61% over the past three months and 53.45% over the past year. The large-value stock has no economic moat. Generali is trading at a 15% premium to its fair value estimate of EUR 25.05, with an Uncertainty Rating of Medium.

Argenx ARGX

• Morningstar Rating: ★★

• One-Month Return: 12.53%

Biotechnology firm Argenx is up 31.43% over the past three months and 89.01% over the past year. The stock’s price is 33% above its fair value estimate of EUR 491, with an Uncertainty Rating of Very High. The mid-growth stock has no economic moat.

Barclays BARC

• Morningstar Rating: ★★

• One-Month Return: -2.08%

Diversified bank Barclays has gained 13.27% over the past three months and 89.48% over the past year. The large-core stock has no economic moat. Barclays is trading at a 15% premium to its fair value estimate of GBX 230, with an Uncertainty Rating of High.

Be Semiconductor Industries BESI

• Morningstar Rating: ★★

• One-Month Return: 9.60%

Semiconductor equipment and materials firm Be Semiconductor Industries is up 22.41% over the past three months and 10.11% over the past year. The stock’s price is 16% above its fair value estimate of EUR 120, with an Uncertainty Rating of High. The mid-growth stock has a narrow economic moat.


This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar’s use of automation.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Bella Albrecht  is associate data journalist at Morningstar

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures